Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Clinical · Molecular biology

Genomic Profiling, Risk Stratification, and Post-Transformation Treatment Outcomes in Patients with Transformed Small-Cell Lung Cancer: A Multicenter Analysis

Summary

This multicenter retrospective study analyzed 163 patients with transformed small-cell lung cancer (T-SCLC), a recognized resistance mechanism in EGFR-mutant lung adenocarcinoma. The study aimed to identify early predictors of histological transformation and evaluate post-transformation treatment outcomes. Researchers found a median transformation time of 25.8 months and a median post-transformation overall survival of 14.2 months in EGFR-mutant patients. A predictive model was developed, incorporating age, RB1/NTRK1 mutations, and secondary EGFR T790M mutation as independent risk factors. Taxane-based regimens emerged as a promising later-line therapeutic option for T-SCLC.

Critical appraisal

Clinical. This multicenter retrospective study establishes a clinically applicable predictive model for early SCLC transformation and risk stratification, addressing a significant resistance mechanism in EGFR-mutant lung adenocarcinoma. The identification of age, RB1/NTRK1 mutations, and secondary EGFR T790M mutation as independent risk factors could guide clinicians in patient surveillance. Furthermore, the finding that taxane-based regimens are a promising later-line therapeutic option (median PFS of 6.93 months) could influence treatment decisions, suggesting a short-to-medium term clinical impact (1-3 years) for optimizing post-transformation therapeutic strategies.

Molecular biology. Genomic profiling, performed using next-generation sequencing (NGS) on paired primary-transformed samples from 60 EGFR-mutant patients, allowed for the characterization of T-SCLC’s molecular features. The discovery that RB1 and NTRK1 mutations, along with the secondary EGFR T790M mutation, are independent risk factors for SCLC transformation provides potential biomarkers for early detection. The study also explored evolutionary diversity, suggesting its association with shorter post-transformation overall survival, which opens avenues for understanding resistance mechanisms and tumor progression. These molecular findings could justify the development of clinical tests based on these biomarkers to identify at-risk patients.

The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology